Indian Journal of Pharmacology Home 

LETTER TO EDITOR
[Download PDF]
Year : 2011  |  Volume : 43  |  Issue : 1  |  Page : 94--95

The novelty of research article: Whose responsibility is it?

Ravindra S Beedimani 
 American University of Caribbean, School of Medicine, St. Maarten, Netherlands Antilles

Correspondence Address:
Ravindra S Beedimani
American University of Caribbean, School of Medicine, St. Maarten, Netherlands Antilles




How to cite this article:
Beedimani RS. The novelty of research article: Whose responsibility is it?.Indian J Pharmacol 2011;43:94-95


How to cite this URL:
Beedimani RS. The novelty of research article: Whose responsibility is it?. Indian J Pharmacol [serial online] 2011 [cited 2022 Jan 23 ];43:94-95
Available from: https://www.ijp-online.com/text.asp?2011/43/1/94/75689


Full Text

Sir,

I would like to comment on the article entitled "Effective control of sickle cell disease with hydroxyurea therapy" [1] published in Jan-Feb, 2010 issue of Indian Journal of Pharmacology. I have found nothing novel about the topic which makes it to be published. Any research article must meet certain criteria and standards that are set by the editorial and review committee before it can be published. That said, I saw nothing novel in the study, the main objective of which was the evaluation of hydroxyurea therapy in sickle cell patients. This has already been well studied and established for some time; [2],[3] indeed, this is referenced in the article itself and in standard pharmacology texts. [4],[5] In the 15 years that I have instructed undergraduate and postgraduate medical students in Pharmacology, I have routinely taught about the effectiveness and safety of hydroxyurea in the control of sickle cell disease. I would therefore enquire the authors and other concerned members about the criteria that merited publication of the article in the journal.

References

1Singh H, Dulhani N, Kumar BN, Singh P, Tiwari P. Effective control of sickle cell disease with hydroxyurea therapy. Indian J Pharmacol 2010;42:32-5.
2Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999;94:3022-6.
3Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984;74:652-6.
4Cokic VP, Smith RD, Beleslin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003;111:231-9.
5Franco RS, Yasin Z, Palascak MB, Ciraolo P, Joiner CH, Rucknagel DL. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood 2006;108:1073-6.